Our website uses cookies to distinguish you from other users of our site. This helps us to continually improve your experience when using our website. We also use external analytics software which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our site Privacy and Cookie Policies. You can delete or disable these cookies in your web browser at any time but doing so may impact website functionality and user experience.

ApcinteX, Morphogen-IX, Z Factor join seven other privately held biotech companies in a new type of pharmaceutical R&D model.

 

Centessa Pharmaceuticals launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Its asset-centric R&D model, applied at scale, has assembled best-in-class or first-in-class assets, each of which is led by specialised teams committed to accelerate development and reshape the traditional drug development process.

Centessa was founded by Medicxi, which has raised $250 million in an oversubscribed Series A financing led by General Atlantic and co-led by Vida Ventures and Janus Henderson Investors. Additional blue-chip investors participated in the financing, including Boxer Capital, Cormorant Asset Management, T. Rowe Price Associates Inc, Venrock Healthcare Capital Partners, Wellington Management Company, BVF Partners L.P., EcoR1 Capital, Franklin Templeton, Logos Capital, Samsara BioCapital, LifeSci Venture Partners, and an undisclosed US-based, healthcare-focused fund.

In conjunction with its launch, Centessa has completed the merger of ten private biotech companies that will each continue to develop their assets, with oversight from the Centessa management team. Each subsidiary is asset-focused, prosecuting a single program or biological pathway, with leadership provided by subject matter experts given a high degree of autonomy to advance each program. With a singular focus on advancing exceptional science, combined with proprietary capabilities, including structure-based drug discovery and design, the subsidiary teams enable Centessa to potentially develop and deliver impactful medicines to patients.

Centessa brings together ten companies from Medicxi’s portfolio. Together they have 15 high-conviction programs. Each Centessa Subsidiary is led by industry leaders and subject matter experts with deep expertise directly related to key biological pathways that underpin the programs. These entrepreneurs, who have catalysed the creation of subsidiary companies, will continue to advance novel science within Centessa. The subsidiaries are ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, Pega-One, and Z-Factor.

The current Centessa portfolio consists of four clinical stage programs, including two that are in late-stage clinical development, and more than ten additional programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Additional information on Centessa Pharmaceuticals may be found here.

The vision of Centessa is to build a pharmaceutical company with a unique operational framework that aims to reduce some of the key R&D inefficiencies that classical pharmaceutical companies face because of structural constraints. The ambition of applying asset-centricity at scale is to be able to deliver life altering medicines to patients with improved efficiency by boosting R&D productivity.

Francesco De Rubertis, Board Chairman, Centessa Pharmaceuticals; Co-founder and Partner at Medicxi

With this first-of-its-kind model, we are bringing together programs with robust genetic and biological validation under one new pharmaceutical company that provides centralized resources to enable and empower asset-focused teams to advance highly impactful programs for patients.

Saurabh Saha, CEO, Centessa Pharmaceuticals

We have strategically assembled our subsidiary portfolio to include programs with strong biological validation, mechanistic diversification, and teams with proprietary capabilities and insights. This high quality portfolio aims to deliver enhanced diversification, reduced risk. and asymmetric upside with a view to withstanding the inherent low probability of success associated with drug development.

Moncef Slaoui, CSO, Advisor, Centessa Pharmaceuticals

Make a media enquiry

If you are a journalist with a media enquiry, please contact our Press and Media Manager.

Make a media enquiry